Figure 4: Meta-analysis of BCC, glioblastoma, melanoma, and HNSCC reveals a general prognostic role for aPD1-induced BCR diversity.

A) ∆BCR clonotype count from pre-PD1 inhibitor to post-PD1-inhibitor of patients with progressed tumors vs. non-progressed tumors.

B) Kaplan-Meier curve of overall survival for aggregate cancer patients stratified by induced BCR expansion from PD-1 inhibitor.

C) Hazard ratios of overall survival for aggregate cancer patients by BCR or TCR clonotype. An increased clonotype diversity is defined by a greater number of clonotypes detected in post-PD1 treated tumors compared to prior. Diversity in the case of static measurements at baseline or on-treatment are defined as an above-median BCR or TCR clonotype count.

D) Left: Volcano plot of differentially expressed genes in pre-treatment tumors that undergo induced BCR expansion vs. those without. Right: GO-terms enriched in pre-treatment tumors that undergo induced BCR expansion vs. those without.

E) Left: Volcano plot of differentially expressed genes in post-treatment tumors that undergo induced BCR expansion vs. those without. Right: GO-terms enriched in post-treatment tumors that undergo induced BCR expansion vs. those without